BOLD Audentes Therapeutics Inc.

-0.86  -2%
Previous Close 36.9
Open 36.86
Price To Book 3.55
Market Cap 1571117525
Shares 43,593,716
Volume 247,424
Short Ratio
Av. Daily Volume 516,292

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 updated data due 2Q 2019.
Next update at American Society of Gene and Cell Therapy (ASGCT) - April 29-May 2, 2019.
X-Linked Myotubular Myopathy

Latest News

  1. Spark Unlikely To Get A Better Bid — But These Stocks Could Be In Play
  2. 10 Stocks For The Gene Therapy Revolution
  3. Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  4. Introducing Audentes Therapeutics (NASDAQ:BOLD), The Stock That Dropped 10% In The Last Year
  5. Audentes Therapeutics (BOLD) Upgraded to Buy: Here's What You Should Know
  6. Edited Transcript of BOLD earnings conference call or presentation 27-Feb-19 9:30pm GMT
  7. Audentes Therapeutics Inc (BOLD) Files 10-K for the Fiscal Year Ended on December 31, 2018
  8. Audentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Program to Support Patients Living with Rare Diseases
  9. Audentes Therapeutics, Inc. (BOLD) Q4 2018 Earnings Conference Call Transcript
  10. Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update
  11. Biotech ETFs Jump on Roche-Spark Deal
  12. Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019
  13. Audentes Therapeutics to Participate in Upcoming Investor Conferences
  14. Report: Developing Opportunities within Dunkin' Brands Group, Murphy Oil, NII, Audentes Therapeutics, RealNetworks, and MDC Partners — Future Expectations, Projections Moving into 2019
  15. Mizuho's 9 Best Biotech Stocks to Buy for 2019
  16. Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation
  17. Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities